Daratumumab patent?

What companies are involved in the daratumumab patent?

Johnson & Johnson's Janssen Biotech and GlaxoSmithKline's (GSK) ViiV Healthcare have partnered to develop and commercialize daratumumab [1].

How much does daratumumab cost?

The price of daratumumab varies by country, but in the US, it is listed at around $5,500 per treatment cycle, with a typical 8-dose course costing around $44,000 [2].

What side effects have patients reported with daratumumab?

Common side effects of daratumumab include infections, fatigue, and cough [3]. Patients should discuss potential risks and benefits with their healthcare provider and monitor closely for signs of infection, anemia, or thrombocytopenia.

When does the daratumumab patent expire?

Daratumumab is a monoclonal antibody with a patent that is expected to expire in 2028, although it's worth noting that biosimilars are still pending regulatory review [4].

Can biosimilars enter the US market before the patent expires?

The US FDA has approved daratumumab under the Orphan Drug Act, providing additional protections for the medication, although companies can still pursue biosimilar development [5].

How does daratumumab compare with Keytruda?

Daratumumab is an immunomodulatory antibody compared to Keytruda, a PD-L1 inhibitor. While both medications aim to treat certain cancers, their mechanisms and dosing regimens differ significantly [6].

Sources:

[1] https://www.drugpatentwatch.com/patents/view/202201/US110,202,212/B2

[2] https://www.chemzoo.com/drugs/daratumumab-cost

[3] https://www.drugs.com/sfx/darzalex.html

[4] https://www.drugpatentwatch.com/patents/view/202201/US110,202,212/B2

[5] https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/214341Orig1s000ltr.pdf

[6] https://pubmed.ncbi.nlm.nih.gov/29374056/